Pictet Asset Management Holding SA Purchases 491,181 Shares of Abbott Laboratories $ABT

Key Points

• Pictet Asset Management raised its stake in Abbott by 54.5%, buying 491,181 shares to hold 1,393,242 shares worth about $174.6 million (≈0.08% of the company) at the end of the quarter.
• Abbott slightly beat Q1 estimates with $1.15 EPS (vs. $1.14 consensus) and $11.16B revenue (up 7.8% YoY), and set FY2026 guidance of 5.380–5.580 EPS and Q2 guidance of 1.250–1.310, while analysts’ consensus EPS is ~5.48 and the consensus price target is $119.43.
• Insiders recently bought shares (CFO purchased 2,200 at $91.50; a director purchased 10,000 at $108.73), Abbott declared a $0.63 quarterly dividend (2.7% yield), and the stock is trading near its 52‑week low (around $92).

Pictet Asset Management Holding SA boosted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 54.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,393,242 shares of the healthcare product maker's stock after acquiring an additional 491,181 shares during the quarter. Pictet Asset Management Holding SA owned 0.08% of Abbott Laboratories worth $174,557,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Harbor Capital Advisors Inc. bought a new position in Abbott Laboratories in the 4th quarter valued at approximately $27,000. Cloud Capital Management LLC bought a new position in Abbott Laboratories in the 3rd quarter valued at approximately $29,000. Guerra Advisors Inc bought a new position in Abbott Laboratories in the 3rd quarter valued at approximately $31,000. Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories in the 3rd quarter valued at approximately $33,000. Finally, Copia Wealth Management bought a new position in Abbott Laboratories in the 3rd quarter valued at approximately $38,000. 75.18% of the stock is owned by institutional investors.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau purchased 2,200 shares of the firm's stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the firm's stock in a transaction dated Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares of the company's stock, valued at $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Trading Up 1.9%

Shares of NYSE ABT opened at $92.85 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. Abbott Laboratories has a 52-week low of $90.72 and a 52-week high of $139.06. The firm has a 50 day moving average price of $105.56 and a two-hundred day moving average price of $116.83. The stock has a market cap of $161.71 billion, a P/E ratio of 26.01, a price-to-earnings-growth ratio of 1.52 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The firm had revenue of $11.16 billion during the quarter, compared to analysts' expectations of $10.99 billion. During the same period in the prior year, the company posted $1.09 EPS. The company's revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories's dividend payout ratio is 70.59%.

Analyst Upgrades and Downgrades

ABT has been the subject of several research reports. Royal Bank Of Canada dropped their price objective on shares of Abbott Laboratories from $135.00 to $130.00 and set an "outperform" rating for the company in a research note on Friday, April 17th. UBS Group dropped their price objective on shares of Abbott Laboratories from $158.00 to $135.00 and set a "buy" rating for the company in a research note on Monday, April 20th. Piper Sandler dropped their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an "overweight" rating for the company in a research note on Friday, April 17th. Benchmark dropped their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating for the company in a research note on Friday, April 17th. Finally, Leerink Partners dropped their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $119.43.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.